WO2005103037A3 - Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments - Google Patents

Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments Download PDF

Info

Publication number
WO2005103037A3
WO2005103037A3 PCT/EP2005/004104 EP2005004104W WO2005103037A3 WO 2005103037 A3 WO2005103037 A3 WO 2005103037A3 EP 2005004104 W EP2005004104 W EP 2005004104W WO 2005103037 A3 WO2005103037 A3 WO 2005103037A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
methods
medicaments
cgrp antagonists
salts
Prior art date
Application number
PCT/EP2005/004104
Other languages
German (de)
French (fr)
Other versions
WO2005103037A2 (en
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Gerhard Schaenzle
Kirsten Arndt
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Gerhard Schaenzle
Kirsten Arndt
Henri Doods
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Stephan Georg Mueller, Klaus Rudolf, Philipp Lustenberger, Dirk Stenkamp, Marco Santagostino, Fabio Paleari, Gerhard Schaenzle, Kirsten Arndt, Henri Doods filed Critical Boehringer Ingelheim Int
Priority to EP05735460A priority Critical patent/EP1740577A2/en
Priority to JP2007508815A priority patent/JP2007533689A/en
Priority to CA002565219A priority patent/CA2565219A1/en
Publication of WO2005103037A2 publication Critical patent/WO2005103037A2/en
Publication of WO2005103037A3 publication Critical patent/WO2005103037A3/en
Priority to CA002600909A priority patent/CA2600909A1/en
Priority to KR1020077024324A priority patent/KR20070114831A/en
Priority to MX2007011527A priority patent/MX2007011527A/en
Priority to BRPI0607577-0A priority patent/BRPI0607577A2/en
Priority to EP06723538A priority patent/EP1863799A1/en
Priority to PCT/EP2006/002515 priority patent/WO2006100009A1/en
Priority to RU2007138881/04A priority patent/RU2007138881A/en
Priority to AU2006226615A priority patent/AU2006226615A1/en
Priority to JP2008502299A priority patent/JP2008538209A/en
Priority to TW095109753A priority patent/TW200700408A/en
Priority to US11/277,177 priority patent/US7528129B2/en
Priority to IL186090A priority patent/IL186090A0/en
Priority to US12/707,890 priority patent/US20100144716A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

The invention relates to CGRP antagonists of general formula (I), wherein A, X, Q, and R1 to R3 are defined as indicated in claim 1, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds, the use thereof, and methods for the production thereof.
PCT/EP2005/004104 2004-04-22 2005-04-18 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments WO2005103037A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP05735460A EP1740577A2 (en) 2004-04-22 2005-04-18 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
JP2007508815A JP2007533689A (en) 2004-04-22 2005-04-18 Selected CGRP antagonists, methods for their production and their use as drugs
CA002565219A CA2565219A1 (en) 2004-04-22 2005-04-18 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
JP2008502299A JP2008538209A (en) 2005-03-23 2006-03-18 CGRP antagonists, methods for their production and their use as drugs
AU2006226615A AU2006226615A1 (en) 2005-03-23 2006-03-18 CGRP antagonists, method for the production thereof, and their use as medicaments
MX2007011527A MX2007011527A (en) 2005-03-23 2006-03-18 Cgrp antagonists, method for the production thereof, and their use as medicaments.
KR1020077024324A KR20070114831A (en) 2005-03-23 2006-03-18 Cgrp antagonists, method for the production thereof, and their use as medicaments
CA002600909A CA2600909A1 (en) 2005-03-23 2006-03-18 Cgrp antagonists, method for the production thereof, and their use as medicaments
BRPI0607577-0A BRPI0607577A2 (en) 2005-03-23 2006-03-18 cgrp antagonists, process for preparation as well as use as a medicine
EP06723538A EP1863799A1 (en) 2005-03-23 2006-03-18 Cgrp-antagonists, process for their preparation as well as their use as medicaments
PCT/EP2006/002515 WO2006100009A1 (en) 2005-03-23 2006-03-18 Cgrp antagonists, method for the production thereof, and their use as medicaments
RU2007138881/04A RU2007138881A (en) 2005-03-23 2006-03-18 CGRP-PEPTIDE ANTAGONISTS, METHOD FOR PRODUCING THEM, AND ALSO THEIR APPLICATION AS MEDICINES
TW095109753A TW200700408A (en) 2005-03-23 2006-03-22 New cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions
US11/277,177 US7528129B2 (en) 2005-03-23 2006-03-22 CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
IL186090A IL186090A0 (en) 2005-03-23 2007-09-20 Cgrp antagonists, method for the production thereof, and their use as medicaments
US12/707,890 US20100144716A1 (en) 2005-03-23 2010-02-18 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019492.0 2004-04-22
DE102004019492A DE102004019492A1 (en) 2004-04-22 2004-04-22 Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals

Publications (2)

Publication Number Publication Date
WO2005103037A2 WO2005103037A2 (en) 2005-11-03
WO2005103037A3 true WO2005103037A3 (en) 2006-01-12

Family

ID=35140095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004104 WO2005103037A2 (en) 2004-04-22 2005-04-18 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments

Country Status (9)

Country Link
EP (1) EP1740577A2 (en)
JP (1) JP2007533689A (en)
AR (1) AR049422A1 (en)
CA (1) CA2565219A1 (en)
DE (1) DE102004019492A1 (en)
PE (1) PE20060186A1 (en)
TW (1) TW200606151A (en)
UY (1) UY28859A1 (en)
WO (1) WO2005103037A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10250082A1 (en) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063753A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists in combination with other migraine medicines for the treatment of migraine
DE102004063752A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists to combat menopausal hot flashes
EP1770091A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-antagonists, process for their preparation as well as their use as medicaments
DE102005038831A1 (en) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
DE102005050892A1 (en) 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
PE20080153A1 (en) * 2006-06-08 2008-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING AN ANTAGONIST OF THE PEPTIDE RELATED TO THE CALCITONIN GENE (CGRP)
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
BRPI0817835A2 (en) 2007-10-18 2015-03-31 Boehringer Ingelheim Int CGRP ANTAGONISTS
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
EP2225223B1 (en) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organic compounds
CN103108873A (en) * 2010-07-16 2013-05-15 皮拉马尔企业有限公司 Substituted imidazoquinoline derivatives as kinase inhibitors
AU2014334040A1 (en) 2013-10-07 2016-04-28 Bayer Pharma Aktiengesellschaft Cyclic thienouracil-carboxamides and use thereof
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
WO2017148519A1 (en) 2016-03-03 2017-09-08 Boehringer Ingelheim International Gmbh Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as aoc3 inhibitors
EP3423434B1 (en) 2016-03-03 2020-01-15 Boehringer Ingelheim International GmbH 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as aoc3 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018764A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
WO2001010425A2 (en) * 1999-08-10 2001-02-15 Boehringer Ingelheim Pharma Kg Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2004063171A1 (en) * 2003-01-14 2004-07-29 Boehringer Ingelheim International Gmbh N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as cgrp-antagonists for treating a headache
WO2005095383A1 (en) * 2004-03-29 2005-10-13 Bristol-Myers Squibb Company Heterocyclic cgrp antagonists for the treatment of migraine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004015723A1 (en) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2000018764A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
WO2001010425A2 (en) * 1999-08-10 2001-02-15 Boehringer Ingelheim Pharma Kg Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
WO2004063171A1 (en) * 2003-01-14 2004-07-29 Boehringer Ingelheim International Gmbh N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as cgrp-antagonists for treating a headache
WO2005095383A1 (en) * 2004-03-29 2005-10-13 Bristol-Myers Squibb Company Heterocyclic cgrp antagonists for the treatment of migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASTERNAK A ET AL: "Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 3, 8 February 1999 (1999-02-08), pages 491 - 496, XP004157253, ISSN: 0960-894X *
See also references of EP1740577A2 *

Also Published As

Publication number Publication date
WO2005103037A2 (en) 2005-11-03
TW200606151A (en) 2006-02-16
EP1740577A2 (en) 2007-01-10
DE102004019492A1 (en) 2005-11-10
JP2007533689A (en) 2007-11-22
PE20060186A1 (en) 2006-04-18
AR049422A1 (en) 2006-08-02
CA2565219A1 (en) 2005-11-03
UY28859A1 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
WO2005103037A3 (en) Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
WO2004037811A8 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2009065919A3 (en) Organic compounds
WO2009065920A3 (en) Compounds
UA88163C2 (en) Cgrp antagonists, methods for the production thereof and their use as medicaments
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2007036532A3 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2009065922A3 (en) Organic compounds
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
RS52142B (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
WO2007020261A3 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
NO20070089L (en) DPP-IV inhibitors
NO20062644L (en) DPP-IV inhibitors
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2005100352A8 (en) Selected cgrp-antagonists, their preparation processes and their use as medicaments
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2005121078A3 (en) Substituted cyclopentene compounds
WO2009034029A3 (en) 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
YU30902A (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
WO2004014869A3 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
MX2010003849A (en) Cgrp antagonists.
WO2006034822A8 (en) Novel substituted thiophencarboxylic acid amides, production thereof and use thereof as medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005735460

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2565219

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007508815

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005735460

Country of ref document: EP